Pinealon — Research Overview
Chemical Name: L-Glutamic acid-L-Aspartic acid-L-Arginine Sequence: Glu-Asp-Arg (EDR) Also Known As: Pinealon, EDR peptide, EDR tripeptide Molecular Formula: C15H26N6O8 Classification: Synthetic tripeptide bioregulator / peptide bioregulator / cytomedine / neuroprotective research peptide Origin: Pinealon was developed from analysis of the amino acid composition of bovine brain (pineal gland region) extracts as part of the peptide bioregulator research program of Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. The EDR sequence was subsequently identified as an active fraction of Cortexin — a polypeptide neuroprotective preparation derived from cerebral cortex extracts — and synthesized as a discrete tripeptide for research investigation. Relationship to Epithalon: Pinealon (EDR, Glu-Asp-Arg) and Epithalon (AEDG, Ala-Glu-Asp-Gly) are both pineal-associated short peptide bioregulators developed by the Khavinson group. They share the pineal gland origin of their parental research programs and overlapping neuroprotective and geroprotective research interests, but are structurally distinct with different lengths, sequences, and proposed primary mechanisms: Epithalon acts primarily through telomerase activation and epigenetic effects on circadian gene expression, while Pinealon’s research profile centers on antioxidant neuroprotection, apoptosis modulation, and direct chromatin/DNA interaction in neuronal contexts. Regulatory Status: Not FDA-approved for any therapeutic indication. Not approved in any major regulatory jurisdiction. Research compound. WADA Status: Not specifically prohibited by name on the WADA prohibited list as of current compilation. Category: Neuroprotective tripeptide bioregulator / ROS suppressor / apoptosis modulator / epigenetic gene regulator / neuronal cell viability research tool / aging biology research compound
Research Use Only — Disclaimer
The scientific literature on this page is provided strictly for educational and informational purposes. All Rogue Compounds products are intended for in-vitro laboratory research use only and are not approved by the FDA for human or animal consumption. The studies referenced below are independent third-party peer-reviewed publications. Rogue Compounds makes no claims that any product diagnoses, treats, cures, or prevents any disease or condition. Researchers are responsible for compliance with all applicable local, state, and federal regulations.
What Is Pinealon?
Pinealon is a synthetic tripeptide composed of three amino acids — glutamic acid (Glu), aspartic acid (Asp), and arginine (Arg) — represented in the standard biochemical shorthand as the EDR peptide. It belongs to a class of research compounds known as peptide bioregulators, developed from tissue-specific extracts through the systematic scientific program of Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. This program, developed over several decades beginning in the 1970s, proceeded from the hypothesis that short oligopeptides present in tissue-specific polypeptide extracts carry tissue-specific regulatory information — and that synthetic equivalents of these active fractions could recapitulate the regulatory activity of the parent extract in a chemically defined and reproducible form.
Pinealon’s parent complex is Cortexin — a polypeptide preparation derived from cerebral cortex extracts that has been used clinically in Russia for neurological conditions including acute ischemic stroke, traumatic brain injury, and age-related cognitive decline. The EDR tripeptide was identified as one of the neuroprotectively active fractions within Cortexin and synthesized as a standalone research tool. The simpler tripeptide structure relative to the parent polypeptide complex was proposed to offer advantages in terms of stability, cellular penetration, and reduced risk of immunogenic response while retaining neuroprotective activity.
The research profile of Pinealon is organized around several intersecting biological themes: antioxidant neuroprotection against reactive oxygen species, modulation of apoptosis through caspase-3 and p53 pathways, epigenetic regulation of gene expression through proposed direct interaction with chromatin and DNA, promotion of serotonin synthesis in cortical neurons, anti-hypoxic effects in neuronal and animal models, and potential geroprotective activity in aging brain.
Understanding Pinealon’s proposed mechanism requires understanding a research paradigm that distinguishes it from most peptides in this catalog: the Khavinson group has proposed that short peptides including Pinealon do not act through cell surface receptors — the conventional mechanism for peptide hormones and growth factors — but instead cross cell membranes and nuclear membranes due to their small molecular size, and directly interact with DNA and histone proteins to influence gene expression. This proposed epigenetic regulatory mechanism is both scientifically distinctive and as yet incompletely characterized, but it forms the conceptual core of the Khavinson bioregulator research program.
The Peptide Bioregulator Research Program — Context
The Khavinson peptide bioregulator research program produced a series of synthetic tripeptides and tetrapeptides derived from tissue extracts with proposed tissue-specific regulatory activity. Each peptide was named for the tissue of origin and the postulated function:
Epithalon (AEDG) — from pineal gland; telomerase activation and circadian regulation Pinealon (EDR) — from pineal region / Cortexin; neuroprotection and brain aging Vilon (KE) — from thymus; immune regulation Vesugen (EWW/other) — cardiovascular tissue bioregulator Livagen (KED) — liver bioregulator with vascular effects
All compounds in this program share the same general research paradigm: short peptide → membrane crossing → nuclear penetration → DNA/histone interaction → epigenetic gene regulation. The specific DNA binding sites and target genes proposed for each peptide have been characterized through molecular modeling and in vitro studies in the originating laboratory, with varying degrees of independent external replication.
For Pinealon specifically, molecular docking studies have proposed binding to the DNA minor groove at oligonucleotide sequences complementary to the EDR peptide — including binding sites identified in promoter regions of genes encoding caspase-3 (CASP3), the neurofilament marker NES, the neuroplasticity marker GAP43, APOE (Alzheimer’s disease risk gene), antioxidant enzymes SOD2 and GPX1, and the transcription factors PPARA and PPARG. These predicted binding sites form the molecular basis for the hypothesis that Pinealon can epigenetically regulate the expression of genes specifically relevant to Alzheimer’s disease pathogenesis and aging-associated neurodegeneration.
Mechanism of Action
Cell membrane and nuclear penetration: Due to its very small size as a tripeptide (three amino acids, molecular weight approximately 403 daltons), Pinealon is proposed to cross lipid bilayers including both cell plasma membranes and nuclear membranes. This membrane permeability at small peptide scale distinguishes it from larger peptide hormones that require cell surface receptors. The proposed ability to enter the nucleus and interact directly with chromatin is the mechanistic foundation for the epigenetic regulatory hypothesis. Fluorescent labeling studies of related short peptides in cell culture models have been used to track cellular and nuclear uptake, supporting the feasibility of this proposed mechanism.
Histone binding and chromatin remodeling: Molecular modeling has proposed that Pinealon binds to histone proteins H1, H2B, H3, and H4 — the structural proteins that package DNA in chromatin. Histone binding is proposed to alter chromatin accessibility at specific gene promoters, changing the transcriptional activity of target genes. One specific study demonstrated binding of the EDR peptide to histone H1.3 protein through molecular modeling, with proposed consequences for chromatin structure at the loci of neuroprotective genes.
DNA minor groove binding: Complementary to histone binding, the EDR peptide has been proposed to bind directly to specific DNA sequences in the minor groove — particularly to oligonucleotide sequences matching the predicted DNA binding site of the EDR sequence. Absorption spectroscopy and dynamic light scattering studies confirmed EDR-DNA interaction in solution. The proposed binding site includes the sequence motif oligo(dCG), and the model suggests that Mg2+ ions can promote DNA-EDR interaction by screening the negatively charged phosphate groups of DNA. Binding sites for EDR were identified in the promoter regions of multiple genes relevant to Alzheimer’s disease pathogenesis and neuronal function.
Antioxidant defense — SOD2 and GPX1 upregulation: One of the most consistently documented effects of Pinealon across multiple cell and animal studies is reduction of reactive oxygen species accumulation. Pinealon demonstrated dose-dependent restriction of ROS accumulation in cerebellar granule cells, neutrophils, and pheochromocytoma (PC12) cells under oxidative stress induced by both receptor-dependent and receptor-independent mechanisms. The proposed molecular mechanism involves upregulation of antioxidant enzyme expression — specifically SOD2 (manganese superoxide dismutase) and GPX1 (glutathione peroxidase 1) — through interaction with regulatory sequences in their promoters. SOD2 dismutates superoxide radicals in mitochondria; GPX1 reduces hydrogen peroxide and lipid peroxides using glutathione. Together they represent two of the primary intracellular antioxidant defenses relevant to neurodegeneration.
Apoptosis modulation — caspase-3 and p53: Pinealon has been documented to reduce markers of neuronal apoptosis, primarily through modulation of caspase-3 and p53 expression. Caspase-3 is the central executioner caspase — the proteolytic enzyme that is the final committed step in most apoptotic pathways. P53 is a transcription factor that drives pro-apoptotic gene expression in response to DNA damage and oxidative stress. Reduction of caspase-3 and p53 synthesis by Pinealon’s proposed epigenetic mechanism would attenuate the apoptotic response of stressed neurons — providing a neuroprotective anti-apoptotic effect that has been demonstrated in multiple model systems including hypoxia/ischemia, homocysteine toxicity, and oxidative stress models.
MAPK/ERK pathway modulation: The ERK1/2 (extracellular signal-regulated kinase) pathway plays a central role in neuronal survival, synaptic plasticity, and the balance between cell survival and apoptosis. When neurons are exposed to homocysteine (a neurotoxic amino acid), ERK1/2 is rapidly activated within 2.5 minutes — an activation pattern associated with apoptotic signaling. In the presence of Pinealon, this ERK1/2 activation was delayed to 20 minutes — a delayed activation pattern associated with adaptive survival signaling rather than apoptosis. This ERK1/2 temporal modulation by Pinealon was interpreted as representing a shift from neurotoxic toward neuroprotective signaling in the context of homocysteine stress.
Serotonin synthesis enhancement through 5-tryptophan hydroxylase: Brain cortex cell culture studies demonstrated that Pinealon and related short peptides stimulate expression of 5-tryptophan hydroxylase — the rate-limiting enzyme in serotonin biosynthesis. Molecular analysis identified a CCTGCC nucleotide sequence in the 5-tryptophan hydroxylase (TPH1) gene promoter that was complementary to the EDR peptide binding sequence, and proposed that this binding epigenetically upregulates tryptophan hydroxylase expression, increasing serotonin synthesis. Serotonin in the central nervous system has both neurotransmitter functions and neuromodulatory and neuroprotective roles, linking Pinealon’s proposed TPH1 regulation to its broader neuroprotective and geroprotective research profile.
PPAR transcription factor modulation: PPARalpha and PPARgamma — nuclear receptor transcription factors regulating fatty acid oxidation, glucose metabolism, and inflammatory gene expression — were identified in molecular modeling as potential downstream targets of Pinealon’s epigenetic regulation. PPARalpha drives mitochondrial fatty acid oxidation and has anti-inflammatory effects. PPARgamma is a master adipogenic and insulin-sensitizing transcription factor that also suppresses inflammatory gene expression. Both receptors are expressed in brain tissue and have been implicated in neurodegeneration research. The regulation of PPAR transcription factors by Pinealon represents a metabolic and anti-inflammatory dimension to its proposed neuroprotective activity.
Published Research
Study 1 — Foundational Cell Biology: Pinealon Increases Cell Viability by Suppression of Free Radical Levels
Authors: Khavinson V, Ribakova Y, Kulebiakin K, Vladychenskaya E, Kozina L, Arutjunyan A, Boldyrev A Year: 2011 Journal: Rejuvenation Research PMID: 21978084 Full text: https://pubmed.ncbi.nlm.nih.gov/21978084/
This study was the primary publication establishing Pinealon’s antioxidant and neuroprotective effects in cell culture — defining the dose-dependent ROS suppression and proposing direct genome interaction as the underlying mechanism.
Pinealon demonstrated dose-dependent restriction of ROS accumulation in three distinct cell types: rat cerebellar granule cells (primary neurons), zymosan-activated rat neutrophils, and PC12 pheochromocytoma cells. This multi-cell-type confirmation established the generalizability of the antioxidant effect beyond a single cell line.
At the same time, Pinealon significantly decreased necrotic cell death measured by propidium iodide exclusion test — directly demonstrating cytoprotective effects accompanying the ROS reduction.
Crucially, the dose-response relationship revealed that ROS suppression and reduction of cell mortality reached saturation at lower Pinealon concentrations, while cell cycle modulation continued at higher concentrations. This saturation kinetics at different dose levels provided the key evidence for the conclusion that Pinealon acts through two distinct mechanisms: an antioxidant mechanism at lower doses and a direct genome interaction mechanism at higher doses. The paper concluded that Pinealon is able to interact directly with the cell genome — the mechanistic hypothesis that has organized subsequent research in this program.
The neuroprotective effect was accompanied by a delayed time course of ERK1/2 activation — the kinase shift from rapid-apoptotic to delayed-adaptive signaling that represents the proposed mechanistic basis for Pinealon’s anti-apoptotic effect.
Study 2 — Prenatal Neuroprotection: Pinealon in Hyperhomocysteinemia Model
Authors: Arutjunyan A, Kozina L, Stvolinskiy S, Bulygina Y, Mashkina A, Khavinson V Full text referenced via: PMID 22567179
This study examined Pinealon’s neuroprotective effects in a prenatal stress model — specifically, the hyperhomocysteinemia model in which elevated maternal homocysteine levels during pregnancy represent a known risk factor for offspring neurodevelopmental disorders.
Pregnant rats were exposed to methionine loading to induce elevated homocysteine levels, with or without concurrent Pinealon treatment. Offspring were assessed for cognitive function and brain tissue oxidative stress.
Offspring of Pinealon-treated mothers showed significantly improved spatial orientation and learning ability compared to offspring of untreated hyperhomocysteinemic mothers.
Brain tissue of Pinealon-treated offspring showed marked reductions in both ROS accumulation and necrotic cell count — histological confirmation of reduced neuronal death in the prenatal stress context.
Cerebellar neurons from Pinealon-treated offspring showed greater resistance to oxidative stress in subsequent ex vivo testing — suggesting that Pinealon’s prenatal neuroprotective effect extends to increased intrinsic stress resistance of the offspring neurons, not merely protection during the period of exposure.
Study 3 — Hypoxic Neuroprotection and Caspase-3 Modulation in Aged Animals
Authors: Mendzheritskii AM, Karantysh GV, Ryzhak GA, Dem’ianenko SV (and related work) Year: 2014-2015 Journal: Advances in Gerontology PMID: 26390612 (related clinical publication); PMID: 22567179 (animal model)
These animal studies evaluated Pinealon’s neuroprotective activity in aged rat models under acute hypobaric hypoxia — conditions modeling the neuronal oxygen deprivation relevant to stroke and other ischemic events.
Pinealon administration to aged rats before or after carotid artery occlusion modulated behavioral outcomes and caspase-3 activity in brain structures — providing direct in vivo evidence for Pinealon’s proposed anti-apoptotic mechanism through caspase-3 downregulation.
Animal models navigating mazes showed that Pinealon demonstrated a greater positive effect on navigation learning than parent compound Cortexin — attributed by the investigators to Pinealon’s modulation of the caspase-3 system in hippocampal and other brain structures involved in spatial memory.
The clinical companion study (PMID 26390612) examined synthetic peptides including Pinealon in 32 patients aged 41-83 years with polymorbidity and organic brain syndrome. Pinealon administration slowed the rate of aging by biological age indicators and demonstrated favorable effects on CNS activity — characterized as anabolic neuroprotective activity. The researchers recommended Pinealon as a potential geroprotector in geriatric practice for patients with organic brain syndrome of vascular or traumatic origin.
Study 4 — Alzheimer’s Disease Model: EDR Peptide Prevents Dendritic Spine Loss
Authors: Khavinson V, Linkova N et al. Year: 2021 Journal: Pharmaceuticals (MDPI) Full text: https://www.mdpi.com/1424-8247/14/6/515
This study directly evaluated EDR and KED peptide effects on neuroplasticity and dendritic spine morphology in a 5xFAD mouse model of Alzheimer’s disease — one of the most genetically rigorous preclinical AD models carrying five familial AD mutations.
Daily intraperitoneal administration of the KED peptide in 5xFAD mice from 2 to 4 months of age tended to increase neuroplasticity. Both KED and EDR peptides prevented dendritic spine loss in 5xFAD mice — a critically important finding given that dendritic spine loss is a key early pathological event in Alzheimer’s disease that precedes and predicts cognitive decline.
Molecular modeling and docking studies positioned the EDR peptide in DNA sequences containing all possible combinations of hexanucleotide sequences — identifying binding sites in promoter regions of CASP3, NES, GAP43, APOE, SOD2, PPARA, PPARG, and GPX1 genes.
The authors concluded that the neuroprotective effects of EDR and KED peptides in the AD model can be defined by their ability to prevent dendritic spine elimination and neuroplasticity impairments at the epigenetic level — directly connecting the proposed DNA interaction mechanism to the observable neuroplastic outcomes.
The study noted that analysis suggests further investigation of EDR and KED peptides may be promising for developing neuroprotective agents for prevention and treatment of early-stage Alzheimer’s disease.
Study 5 — Huntington’s Disease Model: EDR Restores Striatal Neuron Spine Morphology
Authors: Khavinson V, Linkova N, Kukanova E et al. Year: 2017 Journal: Journal of Neurology and Neuroscience Full text referenced via: khavinson.info/assets/files/skan/2017-khavinson_lin_kukanova.pdf
This study examined EDR peptide effects in a Huntington’s disease mouse model — extending the neurodegenerative disease research beyond Alzheimer’s to a condition characterized by striatal neuron loss and dendritic spine pathology.
EDR peptide demonstrated capability to restore the morphology of spines in striatum neurons in the HD mouse model — directly addressing the dendritic spine pathology central to Huntington’s disease progression.
Molecular modeling proposed that EDR peptide binds to the specific DNA binding site oligo(dCG) along the DNA minor groove — providing the structural basis for the proposed epigenetic mechanism of dendritic spine protection.
The study was significant for demonstrating that Pinealon’s neuroprotective effects are not restricted to Alzheimer’s disease pathology but extend to another major neurodegenerative condition with distinct mechanisms — suggesting a broad neuroprotective mechanism operating through neuroplasticity preservation rather than disease-specific pathological targeting.
Study 6 — Serotonin Synthesis: Short Peptides Stimulate TPH Expression in Brain Cortex
Authors: Khavinson VK, Linkova NS, Tarnovskaya SI, Umnov R, Elashkina EV, Durnova A Year: 2014 Journal: Bulletin of Experimental Biology and Medicine Full text referenced via: Bull Exp Biol Med. 2014;157:77-80
This study directly characterized the serotonin synthesis-enhancing activity of short Khavinson peptides in brain cortex cell cultures — establishing the tryptophan hydroxylase gene as a molecular target for EDR peptide epigenetic regulation.
A CCTGCC nucleotide sequence in the promoter of the 5-tryptophan hydroxylase (TPH1) gene was identified as complementary to the binding sequences of short peptides including EDR — proposing that these peptides bind this promoter region and epigenetically regulate TPH1 expression.
The study demonstrated that short peptides stimulated serotonin expression in brain cortex cells — providing direct functional evidence for the proposed TPH1 regulation at the level of neurotransmitter output.
The neuro- and geroprotective significance of this serotonin synthesis enhancement was discussed in the context of serotonin’s roles in mood regulation, cognitive function, and the increasing evidence that serotonergic dysfunction is a feature of aging and neurodegeneration — linking the TPH1 epigenetic effect to the broader geroprotective research profile of Pinealon.
Pinealon Compared to Epithalon — Khavinson Pineal Peptide Pair
Pinealon (EDR, 3 amino acids) and Epithalon (AEDG, 4 amino acids) are often discussed together as the two pineal-associated peptide bioregulators in the Khavinson catalog, and their complementary profiles are worth characterizing for researchers considering either.
Epithalon’s primary research distinction is its telomerase activation activity — the capacity to induce telomerase expression in cells, enabling telomere lengthening and the reversal of one major mechanism of cellular senescence. The Epithalon literature includes published evidence of extended lifespan in rodents, reduced tumor incidence, and melatonin production enhancement through pineal gland normalization. The telomerase mechanism makes Epithalon particularly relevant to cellular aging and longevity research.
Pinealon’s research profile, while sharing the neuroprotective and geroprotective orientation of Epithalon, is more specifically focused on acute neuronal protection in stressed or pathological environments — ROS reduction, apoptosis modulation, dendritic spine preservation in neurodegeneration models, and epigenetic regulation of specific neuronal survival genes. Where Epithalon’s research most strongly targets the cellular aging machinery, Pinealon’s research most strongly targets neuronal resilience and neuropathology.
The two compounds are not interchangeable and are often studied together or in sequence by researchers interested in comprehensive CNS and cellular aging biology within the Khavinson paradigm.
Honest Assessment of the Research Limitations
The Pinealon evidence base carries important limitations that distinguish it from the most robustly translated compounds in this catalog.
The research originates predominantly from a single laboratory group — the Khavinson Institute in St. Petersburg — which while highly productive in publishing within its research program, means that independent external replication of specific findings by different groups using different methodologies is less extensive than desirable for high-confidence mechanistic claims.
The proposed epigenetic mechanism — tripeptide crossing membranes to bind DNA and histones — is biologically plausible for very small peptides but remains incompletely validated. The molecular docking studies predicting specific DNA binding sites are computational models that require wet laboratory validation. The link between proposed DNA binding and the observed biological effects (ROS reduction, apoptosis modulation, serotonin enhancement) is mechanistically proposed but not directly demonstrated through receptor identification, competitive inhibitor studies, or genetic experiments that would establish causality.
Human clinical data is limited — the most directly relevant human study involved 72 traumatic brain injury patients receiving Pinealon alongside standard therapy, reporting improvements in memory, headache duration, and cognitive performance. While clinically encouraging, this study lacks the scale, control design, and independent replication that would establish clinical efficacy in the way FDA approval-grade evidence would require. No Phase 2 or 3 controlled clinical trials have been published.
The research is almost entirely from Russian-language journals or Russian investigators publishing in international journals — while this does not invalidate the science, it creates a translational gap in terms of cross-cultural regulatory validation and Western medical literature integration.
Current Research Status
Pinealon is not FDA-approved for any therapeutic indication. No regulatory approval exists in any major Western jurisdiction. Research continues in the Khavinson laboratory and associated groups in Russia on Alzheimer’s disease, Huntington’s disease, aging brain biology, and prenatal neuroprotection. The compound is used clinically in some Eastern European countries within the broader peptide bioregulator tradition, though this use predates rigorous randomized controlled trial evidence. No human Phase 2 or Phase 3 trials have been published as of this research compilation.
Reconstitution Note
Pinealon (EDR) is a synthetic tripeptide supplied as lyophilized powder. Bacteriostatic water is the standard reconstitution solvent. The peptide dissolves readily in aqueous solution due to its hydrophilic amino acid composition. Protect from light. Always confirm the recommended solvent against the specific lot datasheet before reconstitution.
In-Use Period and Storage
Before Reconstitution — Lyophilized Powder
Rogue Compounds stores all products refrigerated prior to shipping to maintain compound integrity from production through to delivery. Upon receipt researchers should store vials at 2 to 8 degrees Celsius immediately. Keep vials sealed, dry, and away from direct light until ready for use. Do not freeze. Repeated freeze-thaw cycling has been documented in peer-reviewed pharmaceutical formulation literature to accelerate structural degradation even in dry powder form, potentially compromising molecular integrity and experimental reproducibility.
Why We Refrigerate Instead of Freeze
Freezing and thawing introduces mechanical and osmotic stress at the molecular level. Published pharmaceutical research identifies freeze-thaw cycling as a significant risk factor for loss of structural integrity in peptides and protein-based compounds. To protect compound quality at every stage of handling and fulfillment, Rogue Compounds maintains refrigerated rather than frozen cold chain storage throughout the entire process.
After Reconstitution — Liquid Solution
Store reconstituted solutions refrigerated at 2 to 8 degrees Celsius immediately after preparation. Protect from light. Avoid repeated freeze-thaw cycles. Use within the timeframe recommended for the individual compound. Label each aliquot with the compound name, concentration, date of reconstitution, and diluent used. Discard any solution that shows visible particulate matter, discoloration, or signs of contamination.
Note: Storage and in-use recommendations on this page are provided as general laboratory guidance based on standard peptide handling practices documented in peer-reviewed pharmaceutical literature. Researchers should always refer to the individual compound’s published research literature and datasheet for any specific requirements. All products sold by Rogue Compounds are intended strictly for in-vitro laboratory research use only.
Available from Rogue Compounds
View the Pinealon product page: https://roguecompounds.com/product/pinealon/